A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVA 23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2018
Price : $35 *
At a glance
- Drugs Pneumococcal vaccine (Primary) ; V 114 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms PNEU-PATH
- Sponsors Merck Sharp & Dohme
- 28 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Oct 2018 Planned End Date changed from 5 Dec 2019 to 30 Dec 2019.
- 07 Oct 2018 Planned primary completion date changed from 5 Dec 2019 to 30 Dec 2019.